AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25733634 — intervention group
Group type: COMPARATOR
Intervention: Change in fat mass
Number of subjects: 25
Study 23228340 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram plus placebo
Number of subjects: 665
Study 23228340 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion sustained-release plus escitalopram
Number of subjects: 665
Study 23228340 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine extended-release plus mirtazapine
Number of subjects: 665
Study 21800009 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg aspirin BID
Number of subjects: 25
Study 21800009 — intervention group
Group type: COMPARATOR
Intervention: 320 mg aspirin OD
Number of subjects: 25
Study 19380597 — intervention group
Group type: EXPERIMENTAL
Intervention: Pagibaximab (10, 30, 60, or 90 mg/kg of body weight)
Number of subjects: 53
Study 19380597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 16271272 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen I: oral praziquantel (40 mg/kg body weight)
Number of subjects: 23
Study 16271272 — intervention group
Group type: COMPARATOR
Intervention: Regimen II: oral ivermectin (200 microg/kg body weight) with oral albendazole (400 mg)
Number of subjects: 23
Study 16271272 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen III: oral ivermectin with oral albendazole and praziquantel
Number of subjects: 23
Study 16271272 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent administration of all three drugs (albendazole, praziquantel, ivermectin)
Number of subjects: 23
Study 15081078 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 227
Study 15081078 — intervention group
Group type: COMPARATOR
Intervention: Teicoplanin
Number of subjects: 227
Study 11062573 — intervention group
Group type: EXPERIMENTAL
Intervention: Centro-central union (CCU)
Number of subjects: 60
Study 11062573 — intervention group
Group type: COMPARATOR
Intervention: Simple transection of the digital nerves (control)
Number of subjects: 60
Study 9052592 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms of misoprostol orally every 4 hours as needed
Number of subjects: 275
Study 9052592 — intervention group
Group type: COMPARATOR
Intervention: Treatment according to established protocol (physician‐chosen combinations of intracervical or vaginal prostaglandins every 4‐6 hours, artificial rupture of membranes, and oxytocin infusion)
Number of subjects: 275
Study 8498881 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.25 mg three times daily from menstrual cycle day 16
Number of subjects: 22
Study 8498881 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.50 mg three times daily
Number of subjects: 22
Study 8498881 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.75 mg three times daily from menstrual cycle day 16
Number of subjects: 22
Study 8498881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 8498881 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 22
Study 3687519 — intervention group
Group type: EXPERIMENTAL
Intervention: BBC TV series 'So You Want To Stop Smoking?'
Number of subjects: 134
Study 3687519 — intervention group
Group type: COMPARATOR
Intervention: Control film of the same length
Number of subjects: 134
Study 30255720 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous delta-9-tetrahydrocannabinol (0.015 mg/kg)
Number of subjects: 23
Study 30255720 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous delta-9-tetrahydrocannabinol (0.03 mg/kg)
Number of subjects: 23
Study 30255720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 27555183 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightwand-guided insertion technique
Number of subjects: 300
Study 27555183 — intervention group
Group type: COMPARATOR
Intervention: Standard insertion technique
Number of subjects: 300
Study 27555183 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 300
Study 24506827 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular second premolar infiltration (SP) with 4% articaine and 1:100,000 adrenaline
Number of subjects: 29
Study 24506827 — intervention group
Group type: COMPARATOR
Intervention: Mandibular first molar infiltration (FM) with 4% articaine and 1:100,000 adrenaline
Number of subjects: 29
Study 21492884 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet 60 mg single dose
Number of subjects: 35
Study 21492884 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 35
Study 21492884 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 3)
Number of subjects: 35
Study 21036880 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg bid) combined with TACE (doxorubicin 50 mg)
Number of subjects: 14
Study 21036880 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (200 mg bid)
Number of subjects: 14
Study 21036880 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg bid)
Number of subjects: 14
Study 21036880 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib combined with TACE
Number of subjects: 14
Study 18408077 — intervention group
Group type: EXPERIMENTAL
Intervention: Renilon 7.5(R) oral supplement, 2 packs of 125-ml daily for 3 months
Number of subjects: 86
Study 18408077 — intervention group
Group type: COMPARATOR
Intervention: Standard care (CTRL)
Number of subjects: 86
Study 15936131 — intervention group
Group type: EXPERIMENTAL
Intervention: Swanson metacarpophalangeal implants
Number of subjects: 215
Study 15936131 — intervention group
Group type: COMPARATOR
Intervention: Sutter metacarpophalangeal implants
Number of subjects: 215
Study 14651229 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular implant overdentures
Number of subjects: 60
Study 14651229 — intervention group
Group type: COMPARATOR
Intervention: Conventional dentures
Number of subjects: 60
Study 10424367 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,000 IU aXa of certoparin
Number of subjects: 341
Study 10424367 — intervention group
Group type: COMPARATOR
Intervention: 5,000 IU aXa of certoparin
Number of subjects: 341
Study 8763801 — intervention group
Group type: EXPERIMENTAL
Intervention: MOS SF-36 questionnaire
Number of subjects: 60
Study 8763801 — intervention group
Group type: EXPERIMENTAL
Intervention: Nottingham Health Profile (NHP)
Number of subjects: 60
Study 8763801 — intervention group
Group type: COMPARATOR
Intervention: Comparison with South Australian elderly general population
Number of subjects: 60
Study 8763801 — intervention group
Group type: COMPARATOR
Intervention: Comparison with groups of Australian subjects with various medical and psychiatric conditions
Number of subjects: 60
Study 8763801 — intervention group
Group type: COMPARATOR
Intervention: Comparison with elderly Adelaide residents from a household survey
Number of subjects: 60
Study 1803828 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 600 mg/daily for 3 months plus local immunosuppressive treatment combined with superovulation and IPI
Number of subjects: 0
Study 1803828 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol for 3 months plus superovulation and IPI
Number of subjects: 0
Study 1803828 — intervention group
Group type: COMPARATOR
Intervention: Superovulation and IPI
Number of subjects: 0
Study 6819028 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein energy supplementation (energy and vitamins with 5-11% of energy from milk protein)
Number of subjects: 153
Study 6819028 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy supplementation (42-80 MJ; 10,000-19,000 kcal/trimester, all from carbohydrate, plus vitamins)
Number of subjects: 153
Study 6819028 — intervention group
Group type: COMPARATOR
Intervention: Vitamin-only supplementation (vitamin C 30 mg daily, iron 3 mg daily)
Number of subjects: 153
Study 31706911 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-match compatible platelets
Number of subjects: 38
Study 31706911 — intervention group
Group type: COMPARATOR
Intervention: Uncross-matched platelets
Number of subjects: 38
Study 31706911 — intervention group
Group type: COMPARATOR
Intervention: Incompatible platelets
Number of subjects: 38
Study 30363663 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-Based Continuous Training (CBCT) intervention
Number of subjects: 0
Study 30363663 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 27297611 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Optimal Timing (DOT) method
Number of subjects: 995
Study 25461789 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-Based Training for Cognitive Behavioral Therapy (CBT4CBT)
Number of subjects: 66
Study 25461789 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 66
Study 25461789 — intervention group
Group type: EXPERIMENTAL
Intervention: WAI‐Tech
Number of subjects: 66
Study 21366709 — intervention group
Group type: EXPERIMENTAL
Intervention: Single ALA‐PDT illumination (75 J/cm², 2 sessions 7 days apart)
Number of subjects: 33
Study 21366709 — intervention group
Group type: COMPARATOR
Intervention: Fractionated ALA‐PDT illumination (20 J/cm² and 80 J/cm², 4 and 6 hours after a single ALA application)
Number of subjects: 33
Study 19681533 — intervention group
Group type: EXPERIMENTAL
Intervention: Concept-based learning activities
Number of subjects: 0
Study 19681533 — intervention group
Group type: COMPARATOR
Intervention: Traditional nursing clinical education model (control group)
Number of subjects: 0
Study 17210046 — intervention group
Group type: EXPERIMENTAL
Intervention: Care from an allergy-trained primary healthcare professional
Number of subjects: 202
Study 17210046 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 202
Study 15570521 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 93
Study 15570521 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 93
Study 11443537 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN alpha) immunotherapy
Number of subjects: 18
Study 9930401 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (0.8 g x 3 capsules/d)
Number of subjects: 30
Study 9930401 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil with vitamin E (FOE) supplementation (0.8 g x 3 capsules/d with 3 IU/g vitamin E)
Number of subjects: 30
Study 9930401 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil with vitamin E (FOE) supplementation
Number of subjects: 30
Study 9930401 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation
Number of subjects: 30
Study 9930401 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) and Fish oil with vitamin E (FOE) supplementation
Number of subjects: 30
Study 7809530 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin (2g/day for 10 days)
Number of subjects: 38
Study 7809530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 2837262 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile cardiopulmonary bypass
Number of subjects: 20
Study 2837262 — intervention group
Group type: COMPARATOR
Intervention: Non-pulsatile cardiopulmonary bypass
Number of subjects: 20
Study 31948337 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast meal with 9 g fat and 25 g sugar
Number of subjects: 25
Study 31948337 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast meal with 28 g fat and 18 g sugar
Number of subjects: 25
Study 31948337 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast meal with 5 g fat and 56 g sugar
Number of subjects: 25
Study 28893130 — intervention group
Group type: EXPERIMENTAL
Intervention: Boost (40% hydrogen peroxide)
Number of subjects: 30
Study 28893130 — intervention group
Group type: EXPERIMENTAL
Intervention: Dash (30% hydrogen peroxide)
Number of subjects: 30
Study 28893130 — intervention group
Group type: COMPARATOR
Intervention: Bite&White (6% hydrogen peroxide)
Number of subjects: 30
Study 28893130 — intervention group
Group type: EXPERIMENTAL
Intervention: All products
Number of subjects: 30
Study 28893130 — intervention group
Group type: EXPERIMENTAL
Intervention: Boost group
Number of subjects: 30
Study 28893130 — intervention group
Group type: EXPERIMENTAL
Intervention: Dash group
Number of subjects: 30
Study 28893130 — intervention group
Group type: EXPERIMENTAL
Intervention: Bite&White treatment
Number of subjects: 30
Study 28893130 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 30
Study 26867667 — intervention group
Group type: EXPERIMENTAL
Intervention: Third molar retention during ORIF
Number of subjects: 64
Study 26867667 — intervention group
Group type: COMPARATOR
Intervention: Third molar removal during ORIF
Number of subjects: 64
Study 26867667 — intervention group
Group type: EXPERIMENTAL
Intervention: Third molar retention and removal during ORIF
Number of subjects: 64
Study 26541501 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy delivered in Spanish (MET‐S)
Number of subjects: 866
Study 26541501 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy delivered in English (MET‐E)
Number of subjects: 866
Study 24345073 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric physiotherapy according to the Coach2Move strategy
Number of subjects: 0
Study 24345073 — intervention group
Group type: COMPARATOR
Intervention: Usual physiotherapy care
Number of subjects: 0
Study 24345073 — intervention group
Group type: EXPERIMENTAL
Intervention: Coach2Move intervention
Number of subjects: 0
Study 21483217 — intervention group
Group type: EXPERIMENTAL
Intervention: First repeated public release (August 29, 2005)
Number of subjects: 1951303
Study 21483217 — intervention group
Group type: COMPARATOR
Intervention: Baseline cesarean section rates
Number of subjects: 1951303
Study 21483217 — intervention group
Group type: COMPARATOR
Intervention: Annual number of deliveries
Number of subjects: 1951303
Study 18300985 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac and bupivacaine (30 mg and 150 mg, respectively)
Number of subjects: 50
Study 18300985 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 50
Study 17030772 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered ALSFRS-R
Number of subjects: 60
Study 17030772 — intervention group
Group type: COMPARATOR
Intervention: Standard evaluator-administered ALSFRS-R
Number of subjects: 60
Study 12728215 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulated soy stanols (1.9 g) in a lemonade-flavored beverage
Number of subjects: 45
Study 12728215 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulated soy stanols (1.9 g) in egg whites
Number of subjects: 45
Study 10789595 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxil 60 mg/m2 every 4 weeks
Number of subjects: 15
Study 10789595 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxil 45 mg/m2 every 3 weeks
Number of subjects: 15
Study 9162611 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 40
Study 9162611 — intervention group
Group type: COMPARATOR
Intervention: Porcine insulin
Number of subjects: 40
Study 1637574 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous salcatonin (100 U/d, continuous infusion for five days)
Number of subjects: 20
Study 1637574 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular salcatonin (100 U/d, single bolus for five days)
Number of subjects: 20
Study 6425913 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg d‐amphetamine
Number of subjects: 5
Study 6425913 — intervention group
Group type: COMPARATOR
Intervention: 10 mg diazepam
Number of subjects: 5
Study 6425913 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower doses of d‐amphetamine
Number of subjects: 5
Study 6425913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 30826599 — intervention group
Group type: EXPERIMENTAL
Intervention: CocoaCHOC (chocolate milk with additional cocoa flavanols)
Number of subjects: 13
Study 30826599 — intervention group
Group type: COMPARATOR
Intervention: CHOC (chocolate milk)
Number of subjects: 13
Study 30826599 — intervention group
Group type: EXPERIMENTAL
Intervention: CocoaCHOC
Number of subjects: 13
Study 30826599 — intervention group
Group type: COMPARATOR
Intervention: CHOC
Number of subjects: 13
Study 29544910 — intervention group
Group type: EXPERIMENTAL
Intervention: Busy day
Number of subjects: 50
Study 29544910 — intervention group
Group type: COMPARATOR
Intervention: Rest day
Number of subjects: 50
Study 27299809 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of ixekizumab every 2 weeks after a starting dose of 160 mg
Number of subjects: 3856
Study 27299809 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of ixekizumab every 4 weeks after a starting dose of 160 mg
Number of subjects: 3856
Study 27299809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3856
Study 27299809 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of ixekizumab every 4 weeks (after week 12 reassignment)
Number of subjects: 3856
Study 27299809 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of ixekizumab every 12 weeks (after week 12 reassignment)
Number of subjects: 3856
Study 27299809 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after week 12 reassignment)
Number of subjects: 3856
Study 27299809 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment of ixekizumab from weeks 0 through 60
Number of subjects: 3856
Study 24521364 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise group
Number of subjects: 179
Study 24521364 — intervention group
Group type: COMPARATOR
Intervention: Stretching and strengthening group
Number of subjects: 179
Study 23190503 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with patients who accepted randomization
Number of subjects: 24
Study 23190503 — intervention group
Group type: COMPARATOR
Intervention: Qualitative interviews with patients who declined randomization
Number of subjects: 24
Study 20436049 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-compliance with non-pharmacological recommendations (diet, fluid restriction, weighing, exercise)
Number of subjects: 830
Study 20436049 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-compliance with exercise
Number of subjects: 830
Study 20436049 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-compliance with daily weighing
Number of subjects: 830
Study 20436049 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-compliance overall
Number of subjects: 830
Study 20436049 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall non-compliance or with weighing and exercise
Number of subjects: 830
Study 18589034 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid meal replacement product
Number of subjects: 24
Study 18589034 — intervention group
Group type: COMPARATOR
Intervention: Solid meal replacement product
Number of subjects: 24
Study 16290981 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 72
Study 16290981 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 72
Study 11932310 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment for 7 days
Number of subjects: 10
Study 11932310 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment for 12 months
Number of subjects: 10
Study 9839822 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 32
Study 9839822 — intervention group
Group type: COMPARATOR
Intervention: Beliefs about pain etiology (cancer vs. non-cancer)
Number of subjects: 32
Study 9839822 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects
Number of subjects: 32
Study 8535040 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative blocks
Number of subjects: 50
Study 8535040 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative blocks (expanded criteria)
Number of subjects: 50
Study 8535040 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled blocks
Number of subjects: 50
Study 2122026 — intervention group
Group type: EXPERIMENTAL
Intervention: IVPB method (gentamicin mixed in 5% dextrose in water)
Number of subjects: 0
Study 2122026 — intervention group
Group type: EXPERIMENTAL
Intervention: ILB method (gentamicin mixed using total nutrient admixture solution)
Number of subjects: 0
Study 2122026 — intervention group
Group type: COMPARATOR
Intervention: Comparison of IVPB and ILB methods
Number of subjects: 0
Study 97711 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium chloride 16 mmol
Number of subjects: 12
Study 97711 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium chloride 32 mmol
Number of subjects: 12
Study 97711 — intervention group
Group type: COMPARATOR
Intervention: Placebo sodium chloride 32 mmol
Number of subjects: 12
Study 97711 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium chloride 16 mmol (chronic)
Number of subjects: 12
Study 97711 — intervention group
Group type: COMPARATOR
Intervention: Placebo sodium chloride (chronic)
Number of subjects: 12
Study 29712630 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate group (received intervention immediately)
Number of subjects: 61
Study 29712630 — intervention group
Group type: COMPARATOR
Intervention: Delayed group (received intervention after 2 months)
Number of subjects: 61
Study 28905221 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous reduction
Number of subjects: 49
Study 28905221 — intervention group
Group type: COMPARATOR
Intervention: Conventional open surgery
Number of subjects: 49
Study 26217065 — intervention group
Group type: EXPERIMENTAL
Intervention: BMAC infusion in NIHF group
Number of subjects: 60
Study 26217065 — intervention group
Group type: EXPERIMENTAL
Intervention: BMAC infusion in IHF group
Number of subjects: 60
Study 26217065 — intervention group
Group type: COMPARATOR
Intervention: Control (standard heart failure care) in IHF group
Number of subjects: 60
Study 26217065 — intervention group
Group type: COMPARATOR
Intervention: Control (standard heart failure care) in NIHF group
Number of subjects: 60
Study 23787916 — intervention group
Group type: EXPERIMENTAL
Intervention: ipilimumab/dacarbazine (DTIC)
Number of subjects: 0
Study 23787916 — intervention group
Group type: COMPARATOR
Intervention: placebo/dacarbazine (DTIC)
Number of subjects: 0
Study 21060160 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination of cow's milk from the mothers' diet (case group)
Number of subjects: 114
Study 21060160 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 114